Status:

COMPLETED

Study in Localized and Disseminated Ewing Sarcoma

Lead Sponsor:

University Hospital Muenster

Conditions:

Ewing's Sarcoma

Eligibility:

All Genders

48-50 years

Phase:

PHASE3

Brief Summary

Ewing Sarcoma Primary objectives: Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves eve...

Detailed Description

EWING 2008 is a joint protocol of European and North American Ewing sarcoma study groups. The protocol is aimed at optimising treatment and treatment results of patients with Ewing sarcomas. The EWING...

Eligibility Criteria

Inclusion

  • Diagnosis: Histologically confirmed Ewing sarcoma of bone or soft tissue.
  • Age and sex: Either sex, age \>48 months (for GPOH patients) and \<50 years at the date of diagnostic biopsy. Younger or elderly patients may be reported to the appropriate office (see section 1.4) but are not included in this study.
  • Registration: ≤ 45 days after diagnostic biopsy/surgery.
  • Start of chemotherapy: ≤ 45 days after diagnostic biopsy/surgery.
  • Informed consent: Must be signed prior to study entry.
  • Performance status: Lansky or Karnofsky score \> 50%, may be modified for handicapped patients.
  • Haematological parameters:
  • Haemoglobin \> 8 g/dl (transfusion allowed),
  • Platelets \> 80.000/µl (transfusion allowed),
  • WBC \> 2000/µl.
  • Cardiac values: LVEF \> 40%, SF \> 28%.

Exclusion

  • More than one cycle of other chemotherapy prior to registration
  • Second malignancy
  • Pregnancy and lactation
  • Concurrent treatment within any other clinical trial, except trials with different endpoints that due to the nature of their endpoints must run parallel to EWING 2008 e.g. trials on antiemetics, antimycotics, antibiotics, strategies for psychosocial support, etc...
  • Any other medical, psychiatric, or social condition incompatible with protocol treatment

Key Trial Info

Start Date :

October 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 31 2019

Estimated Enrollment :

907 Patients enrolled

Trial Details

Trial ID

NCT00987636

Start Date

October 1 2009

End Date

March 31 2019

Last Update

October 22 2019

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University Hopital Essen, Pediatrics III, Hematology/ Oncology, Sarcoma Centre, International Ewing Sarcoma Study Group, West German Cancer Centre

Essen, Germany, 45147

2

University Children´s Hospital, Pediatric Hematology and Oncology

Münster, Germany, 48149

Study in Localized and Disseminated Ewing Sarcoma | DecenTrialz